公开(公告)号：WO1996003371A1

公开(公告)日：1996-02-08

申请号：PCT/JP1995001450

申请日：1995-07-21

Applicant: SAGAMI CHEMICAL RESEARCH CENTER ,  NIPPON SHOJI KAISHA, LIMITED ,  FUJIYAKUHIN COMPANY, LIMITED ,  YAZAWA, Kazunaga ,  SHIKANO, Mayumi ,  MASUZAWA, Yasuo ,  TSUJI, Tomoko ,  YAMAGUCHI, Koji ,  SODA, Yasuji

Inventor： SAGAMI CHEMICAL RESEARCH CENTER ,  NIPPON SHOJI KAISHA, LIMITED ,  FUJIYAKUHIN COMPANY, LIMITED

IPC: C07C235/34

CPC classification number: C07C235/34

Abstract: A novel N-acyl-N-(substituted cinnamoyl)ethylenediamine derivative represented by general formula (I) and serving as an antiphlogistic and/or NGF production accelerator, (wherein R represents the acyl residue of a C16 or higher unsaturated fatty acid; R and R represent each independently hydrogen or lower alkyl; and n represents 1 or 2). This compound is expected to be usable as, for example, an antiphlogistic because it has the activities of O2 production inhibitor in human neutrophilic leukocytes and intracellular phospholipase A2 inhibition, and as a remedy for dementia, spinal cord injury, peripheral nerve injury, diabetic neuropathy and amyotrophic lateral sclerosis because it has the activity of accelerating NGF production.

Abstract translation: 一种由通式（I）表示并用作消炎和/或NGF生产促进剂的新型N-酰基-N-（取代肉桂酰）乙二胺衍生物（其中R 1表示C16或更高级不饱和脂肪酸的酰基残基 酸; R 2和R 3各自独立地表示氢或低级烷基; n表示1或2）。 预期该化合物可用作例如消炎药，因为它具有人嗜中性白细胞中的O 2 - 产生抑制剂和细胞内磷脂酶A2抑制的活性，并且作为痴呆，脊髓损伤，周围神经损伤的补救剂 ，糖尿病性神经病变和肌萎缩性侧索硬化，因为它具有加速NGF生产的活性。

公开(公告)号：WO1997036904A1

公开(公告)日：1997-10-09

申请号：PCT/JP1997001109

申请日：1997-03-31

Applicant: SAGAMI CHEMICAL RESEARCH CENTER ,  YAZAWA, Kazunaga ,  ONIMURA, Kenjiro ,  SHIKANO, Mayumi ,  KONDO, Kiyosi

Inventor： SAGAMI CHEMICAL RESEARCH CENTER

IPC: C07D487/04

CPC classification number: C07D487/14

Abstract: A mitomycin C derivative having an excellent activity of inhibiting non-receptor tyrosine kinases believed to participate in immune diseases, lowered in the selectivity for other protein kinases, and represented by chemical formula (I) wherein R represents a docosahexanoyl group; and medicines containing the same as the active ingredient, especially a non-receptor tyrosine kinase inhibitor.

Abstract translation: 认为参与免疫疾病的非受体酪氨酸激酶抑制活性优异的丝裂霉素C衍生物降低了对其他蛋白激酶的选择性，并且由式（I）表示，其中R表示二十二碳酰基; 以及含有与活性成分相同的药物，特别是非受体酪氨酸激酶抑制剂。